Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Polycythemia Vera 1Neoplasms 1Multi-centric Castleman's Disease 1Melanoma 1Macular dystrophy, corneal type 1 1Lymphoproliferative Disorders 1Lymphadenopathy 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1HIV Infections 1

Interventions

asciminib 8Dasatinib 7nilotinib 6Imatinib Mesylate 5Cyclophosphamide 4ponatinib 3fludarabine phosphate 3bosutinib 3Whole-Body Irradiation 3ruxolitinib 2letermovir 2Tacrolimus 2Specimen Handling 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Methotrexate 2Melphalan 2Cyclosporine 2Busulfan 2venetoclax 1pembrolizumab 1pegylated granulocyte colony-stimulating factor 1decitabine and cedazuridine drug combination 1Vorinostat 1Valganciclovir 1Tyrosine Kinase Inhibitors 1Therapeutics 1Stem Cell Transplantation 1Sirolimus 1Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myeloid, Chronic-Phase × Interferon-alpha × 1 year × Clear all
NCT00015847 2025-08-22

Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia

OHSU Knight Cancer Institute

Phase 2 Terminated
25 enrolled 8 charts
MyeloidOther hematologic neoplasm

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡